

U.S. budget pushes for action on screening technologies for Veterans

11 March 2024

Highlights

- 4DMedical praises lawmakers for including screening technologies in [H.R.4366](#) - Consolidated Appropriations Act, 2024
- These appropriation acts provide budget authority to obligate and expend funds from the U.S. Treasury for specific purposes
- President Biden signed the six-bill, \$460 billion package on Saturday (ET), approving full-year funding for the Department of Veterans Affairs among other offices
- Non-invasive technologies poised to help deliver on the promise of PACT Act
- Through this act Congress seeks a report relating to implementation of non-invasive screening technologies for Veterans

Melbourne, Australia, 11 March 2024: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) today praised the U.S. Congress for including language on “non-invasive FDA-approved screening technologies” in the Fiscal Year 2024 appropriations language that was signed by President Biden.

The PACT Act and 4DMedical

In August 2022, President Biden signed the Sergeant First Class Heath Robinson Honoring Our Promise to Address Comprehensive Toxics (PACT) Act. The law establishes a presumption of service connection for 23 respiratory illnesses and cancers related to the smoke from military burn pits and other toxic exposures. It also streamlines the process by which Veterans apply for benefits to cover the cost of their disability and treatment. The use of new, effective screening technologies addressed in the Appropriations Act will help serve Veterans covered under the PACT Act.

The US\$280 billion commitment over ten years by the U.S. legislature through the PACT Act also enables delivery of critical resources. Evaluation of “existing X-ray imaging equipment to derive four-dimensional models of lung function to identify respiratory illnesses and accompanying loss of lung function” was specifically referenced in the accompanying Appropriation Act report language.

Only weeks after the signing of the PACT Act, initial results from a clinical trial at Vanderbilt University Medical Center were released, validating 4DMedical’s XV Technology™ as an effective tool for evaluating Veterans who deployed near burn pits and presented with unexplained shortness of breath.

4DMedical believes there is a need to support Veterans living with these “invisible wounds of war” through both research and practical clinical care delivery partnerships. Recent Company announcements have highlighted these dual efforts. Most recently, on 1 March 2024 the Company announced participation in a U.S. Department of Veterans Affairs Military Exposures Research Program (MERP) grant awarded to the Nashville VA Medical Center and Vanderbilt University Medical Center.

Melbourne

Level 7 Melbourne Connect
700 Swanston Street
Carlton VIC 3053
Tel: +61 (3) 9545 5940

Los Angeles

21255 Burbank Boulevard
Suite 120
Woodland Hills CA 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4DMedical.com
www.4DMedical.com



Additionally, 4DMedical announced a teaming agreement with Philips on 22 January 2024. This agreement established a strategic collaboration to advance solutions for evaluating Veterans with respiratory issues, whereby Philips and 4DMedical will deliver non-invasive lung screening in support of the PACT Act.

Appropriations Act language pushes for action

Additional language was included as part of [H.R.4366](#) - Consolidated Appropriations Act of 2024, signed by President Biden on 9 March 2024 (Eastern Time). Specifically discussing non-invasive lung function screening, the Bill's associated report states: "The Committee notes that the Department has increased its research into Veterans with deployment-related respiratory disease and strongly encourages the Department to continue its efforts to identify and use in clinical practice non-invasive FDA-approved screening technologies that save Veterans from invasive procedures such as surgical lung biopsies that are often required to establish a diagnosis."

Notably, the report also states: "The Committee directs the Department to submit a report to the Committees on Appropriations of both Houses of Congress on their efforts relating to such implementation no later than 90 days after the enactment of this Act."

4DMedical MD/CEO and Founder Andreas Fouras commented:

Five and a half million Veterans have deployed to conflicts in the middle East and been exposed to airborne hazards such as burn pits. Many of them now suffer from debilitating respiratory diseases which existing technologies fail to detect. It's clear non-invasive FDA-approved screening technologies, such as 4DMedical's XV Technology®, will help more people get the right medical assistance sooner. We are pleased this language on screening technologies was included in the new law and look forward to building on our recent momentum, and work with Congress and the VA to help Veterans get the help they need and deserve.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Chief Financial Officer
Simon Glover
sglover@4dmedical.com

Administration

Company Secretary
Naomi Lawrie
companysecretary@4dmedical.com

Media Enquiries

The Capital Network (TCN)
Julia Maguire
julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) – the



first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

In December 2023, 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio's regulatory-cleared solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity and more personalised care for patients.

To learn more, please visit www.4dmedical.com and www.imbio.com.